The FDA has approved FluMist, a nasal spray flu vaccine, for at-home use, offering a convenient and accessible option for individuals ages 18 to 49. This approval expands on the existing use of FluMist for children and adolescents ages 2 to 17, allowing their caregivers to administer the spray. The move comes after clinical trials demonstrated the safety and effectiveness of self-administering the vaccine, making flu protection more accessible for a wider population.
Results for: Flu Vaccine
Pfizer and BioNTech’s combined mRNA vaccine for influenza and COVID-19 has shown mixed results in a Phase 3 trial. While it met one of its primary immunogenicity objectives, it demonstrated lower responses against the influenza B strain compared to a licensed flu vaccine. The companies are evaluating adjustments to improve the vaccine’s effectiveness.